Prevalence of clinically actionable genotypes and medication exposure of older adults in the community

Figures

• 

  Figure 1. Frequency of medium-risk and high-risk actionable genotypes with strong evidence levels in participants taking medications. Notes: The frequency of participants who had an actionable genotype for clopidogrel, statins, warfarin, or thiopurines and were taking a relevant medication is given with respect to the total number of participants for whom medication and genotype data were available (N=1963). There were no participants who had an actionable genotype and were taking thiopurines, and no participants were taking tacrolimus.

• 

  Figure 2. Frequency of actionable genotypes with moderate evidence levels in participants taking statins. Notes: The frequency of participants who had particular actionable statin-related genotypes and were taking a relevant statin are shown: (A) with respect to the total number of participants for whom medication and genotype data were available (N=1963) and (B) with respect to the number of participants with actionable genotypes for each of the subgroups listed. As noted in the text, the GATM rs1346268 variant and the upstream GATM 5′ rs1719247 variant were considered as a single haplotype for analysis purposes.